[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![$650mm Graphic](https://lunarcrush.com/gi/w:26/t:$650mm.png) $650mm

$650mm sees increased mentions and creator activity, with investors eyeing $RARE amidst financial discussions and market analysis.

### About $650mm
This topic refers to discussions and analysis surrounding the financial performance and market activity of a company or asset with a $650mm revenue.  

### Insights [#](/topic/$650mm/insights)
- $650mm creators is up XXX% from the previous month.
- $650mm mentions is up XXXXXX% from the previous week.
- $650mm Creators hit a high of X for the day
- $650mm Creators hit an all time of X for the day
- $650mm Mentions hit a high of X for the day
- $650mm Mentions hit an all time of X for the day

### Engagements: XX [#](/topic/$650mm/interactions)
---
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$650mm/c:line/m:interactions.svg)  
[Engagements 24-Hour Chart Data](/topic/$650mm/time-series/interactions.tsv)  
**Current Value**: XX  
**Daily Average**: XXX  
**1 Month**: XXXXX -XX%  
**1-Year High**: XXXXX on 2025-05-05  
**1-Year Low**: X on 2025-06-22  

| Social Network | X  |
| -------------- | -  |
| Engagements    | XX |
  

  
  
### Mentions: X [#](/topic/$650mm/posts_active)
---
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$650mm/c:line/m:posts_active.svg)  
[Mentions 24-Hour Chart Data](/topic/$650mm/time-series/posts_active.tsv)  
**Current Value**: X  
**Daily Average**: X  
**1 Week**: X +167%  
**1 Month**: XX +86%  
**1-Year High**: X on 2025-07-19  
**1-Year Low**: X on 2025-04-27  

| Social Network | X |
| -------------- | - |
| Mentions       | X |
  

  
  
### Creators: X [#](/topic/$650mm/contributors_active)
---
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$650mm/c:line/m:contributors_active.svg)  
[Creators 24-Hour Chart Data](/topic/$650mm/time-series/contributors_active.tsv)  
X unique social accounts have posts mentioning $650mm in the last XX hours which is no change from in the previous XX hours
**Daily Average**: X  
**1 Week**: X +150%  
**1 Month**: X +200%  
**1-Year High**: X on 2025-07-19  
**1-Year Low**: X on 2025-04-27  

**Top assets mentioned**
In the posts about $650mm in the last XX hours

[SuperRare (RARE)](/topic/$rare)
[SuperRare (RARE)](/topic/superrare)
[Core Scientific, Inc. Common Stock (CORZ)](/topic/$corz)
[MP Materials Corp. (MP)](/topic/$mp)

**Top topics mentioned**
In the posts about $650mm in the last XX hours

[$rare](/topic/$rare), [investment](/topic/investment), [$450mm](/topic/$450mm), [superrare](/topic/superrare), [ipo](/topic/ipo), [reliance](/topic/reliance), [germany](/topic/germany), [drugs](/topic/drugs), [$414mm](/topic/$414mm), [$550mm](/topic/$550mm), [$coz](/topic/$coz), [$3b](/topic/$3b), [rating agency](/topic/rating-agency), [$corz](/topic/$corz), [reit](/topic/reit), [primary market](/topic/primary-market), [money](/topic/money), [$mp](/topic/$mp)

### Top Social Posts [#](/topic/$650mm/posts)
---
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"@LBR_ZA I certainly know their worth. Great place to start adding with CCs. Not as dramatic but $RARE is another to keep your eye on with $650mm annual revenue $450mm cash clean record with the FDA until this recent delay. Investors are worried about dilution now with the delay"  
[@ilzizzo](/creator/x/ilzizzo) on [X](/post/tweet/1946769541004251424) 2025-07-20 03:10:02 UTC 1728 followers, XX engagements


"$MP Seems like people who bought $650MM public offering already made money 😅"  
[@AC_newtothis](/creator/x/AC_newtothis) on [X](/post/tweet/1945847579683491942) 2025-07-17 14:06:29 UTC XXX followers, XX engagements


"$RARE remains a moderate risk high-reward investment. The Orbit studys adherence to its 18-month timeline and their clean FDA approval record (4-for-4 no CRLs) strengthen its long-term potential in the rare disease space. UX111s delay is a manageable hurdle anticipated approval in 2026 - They have roughly $550mm in cash with $414mm burn and projected to do $650mm in revenue this year. Cash burn and potential dilution risk warrant caution. For risk-tolerant investors with a 24+ month horizon with a target of $65$85 by end-2026 if pipeline milestones are met. A Hold or Watch stance is prudent"  
[@ilzizzo](/creator/x/ilzizzo) on [X](/post/tweet/1945719305892659570) 2025-07-17 05:36:46 UTC 1727 followers, XXX engagements


"$RARE $NNNN Both have the same valuation. One has $650mm in annual revenue spread across X drugs (1 brings in about half) with a growing pipeline never received a CRL reaching new ATLs now and the other has legitimacy accusations - A Chinese-owned entity headquartered in Germany primarily focuses on IVD products with a heavy reliance on COVID-related testing. Theyre fresh out of an IPO with 1.6mm in Class A ordinary shares. Gotta love this market"  
[@ilzizzo](/creator/x/ilzizzo) on [X](/post/tweet/1945219306356428926) 2025-07-15 20:29:57 UTC 1731 followers, XXX engagements